AWS Networking Expert and Co-Author of “AWS Certified Advanced Networking Study Guide” Joins Aviatrix
22.2.2021 17:00:00 EET | Business Wire | Press release
Aviatrix, the cloud network platform, today announced that James Devine, formerly from AWS, has joined the company as a Principal Solutions Architect. While at AWS, Devine co-authored the AWS Certified Advanced Networking Study Guide and played an active role in defining cloud reference architectures for some of largest AWS customers. The company also recently added other cloud networking luminaries to its elite Solutions Architecture & Engineering team, including two former Microsoft Azure network specialists, with “Global Black Belt for Azure Networking,” classification; Manny Calero and Bryan Ashley (2 of only 10 people in the world that have this status), along with John Gonsalves, Citigroup’s former Global Head of Network Engineering.
Members of the Aviatrix Solutions Architecture & Engineering team share a common passion for cloud networking, security, and operational simplicity. This team fully understands each customer’s vision and challenges associated with cloud transformation, and helps organizations design and solve complex cloud networking and security problems in a simple and innovative way, the right way, the cloud way.
“I’m very excited to join the Aviatrix team,” said James Devine, Principal Solutions Architect at Aviatrix. “In my previous role as a networking specialist at AWS, I’ve actually recommended Aviatrix to numerous customers where the AWS platform alone couldn’t provide the visibility, control and multi-cloud capabilities they were looking for. I love working with customers, helping them design their cloud network strategies, and by using Aviatrix, our customers will experience a much smoother and more pleasant experience as they transition to multi-cloud.”
These significant additions to the Aviatrix team further validate the company’s cloud network platform, its MCNA (Multi-cloud Network Architecture) approach, and the rapid innovation that Aviatrix is bringing to cloud networking. As transformation to multi-cloud is quickly becoming essential for every organization, customers are demanding more advanced networking capabilities with a simple repeatable architecture that extends to multiple regions and multiple clouds. The top talent that Aviatrix is attracting is driving the future of cloud networking by bringing simplicity, security, operational efficiency, and advance controls for our customers. James, Manny, Bryan, and John, along with existing members of the Solutions Architecture & Engineering team, are playing a key role in defining product direction and helping with cloud architecture and design for some of the world’s largest brands. They’re also developing multi-cloud network training as part of the company’s well-recognized and respected “ACE Program,” which recently surpassed 10k certified engineers in just under a year. This program is the first multi-cloud networking and security certification available to cloud practitioners, DevOps, networking staff, and security professionals.
“We’re thrilled to have James join our team,” stated Nauman Mustafa, Vice President Solutions Engineering, at Aviatrix. “Our elite group of cloud networking experts has many years of expertise in designing and managing network infrastructures. And now they’ve all joined Aviatrix with one thing in common – to provide the best cloud networking solutions and experience to our customers.”
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005214/en/
Contact information
PR Contact:
Aviatrix
Dmitry Lipkin
dlipkin@aviatrix.com
408-888-2792
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom